Asthma prescribing according to Arg16Gly beta-2 genotype: a randomised trial in adolescents

Ruffles, Thomas, Jones, Christina J, Palmer, Colin, Turner, Steve, Grigg, Jonathan, Tavendale, Roger, Hogarth, Fiona, Rauchhaus, Petra, Pilvinyte, Kristina, Hannah, Romanie, Smith, Helen, Littleford, Roberta, Lipworth, Brian and Mukhopadhyay, Somnath (2021) Asthma prescribing according to Arg16Gly beta-2 genotype: a randomised trial in adolescents. European Respiratory Journal. ISSN 0903-1936

[img] PDF - Other
Restricted to SRO admin only

Download (1MB)
[img] PDF - Accepted Version
Restricted to SRO admin only until 22 January 2022.

Download (4MB)

Abstract

Introduction The A allele of rs1042713 (Arg16 amino acid) in the beta-2 (β2) adrenoreceptor is associated with poor response to long-acting β2-agonist (LABA) in young people with asthma. Our aim was to assess whether the prescribing of second line controller with LABA or a leukotriene receptor antagonist (LTRA) according to Arg16Gly genotype would result in improvements in pediatric asthma-related quality of life questionnaire (PAQLQ).

Methods We performed a pragmatic randomised controlled trial (RCT) via a primary care clinical research network covering England and Scotland. We enrolled participants aged 12–18 years with asthma taking inhaled corticosteroids. A total of 241 participants (mean (sd) age 14.7 years (1.91)) were randomised (1:1) to receive personalised care (genotype directed prescribing) or standard guideline care. Following 4-week run-in participants were followed for 12-months. The primary outcome measure was change in PAQLQ. Asthma control, asthma exacerbation frequency and healthcare utilisation were secondary outcomes.

Results Genotype directed prescribing resulted in an improvement in PAQLQ compared to standard care 0.16, (95%CI 0.00–0.31; p=0.049), although this improvement was below the pre-determined clinical threshold of 0.25. The AA genotype was associated with a larger improvement in PAQLQ with personalised versus standard care 0.42, (95%CI 0.02–0.81; p=0.041).

Conclusion This is the first RCT demonstrating that genotype driven asthma prescribing is associated with a significant improvement in a clinical outcome compared to standard care. Adolescents with the AA homozygous genotype benefited most. The potential role of such β2-adrenoceptor genotype directed therapy in younger and more severe childhood asthma warrants further exploration.

Item Type: Article
Schools and Departments: Brighton and Sussex Medical School > Clinical and Experimental Medicine
Brighton and Sussex Medical School > Primary Care and Public Health
SWORD Depositor: Mx Elements Account
Depositing User: Mx Elements Account
Date Deposited: 08 Jan 2021 16:33
Last Modified: 11 Feb 2021 11:45
URI: http://sro.sussex.ac.uk/id/eprint/96343

View download statistics for this item

📧 Request an update